Toxicity of Doxorubicin on Pig Liver After Chemoembolization with Doxorubicin-loaded Microspheres: A Pilot DNA-microarrays and Histology Study
The potential mechanisms accounting for the hepatotoxicity of doxorubicin-loaded microspheres in chemoembolization were examined by combining histology and DNA-microarray techniques.
The left hepatic arteries of two pigs were embolized with 1 mL of doxorubicin-loaded (25 mg; (DoxMS)) or non-loaded (BlandMS) microspheres. The histopathological effects of the embolization were analyzed at 1 week. RNAs extracted from both the embolized and control liver areas were hybridized onto Agilent porcine microarrays. Genes showing significantly different expression (p < 0.01; fold-change > 2) between two groups were classified by biological process.
At 1 week after embolization, DoxMS caused arterial and parenchymal necrosis in 51 and 38 % of embolized vessels, respectively. By contrast, BlandMS did not cause any tissue damage. Up-regulated genes following embolization with DoxMS (vs. BlandMS, n = 353) were mainly involved in cell death, apoptosis, and metabolism of doxorubicin. Down-regulated genes (n = 120) were mainly related to hepatic functions, including enzymes of lipid and carbohydrate metabolisms. Up-regulated genes included genes related to cell proliferation (growth factors and transcription factors), tissue remodeling (MMPs and several collagen types), inflammatory reaction (interleukins and chemokines), and angiogenesis (angiogenic factors and HIF1a pathway), all of which play an important role in liver healing and regeneration.
DoxMS caused lesions to the liver, provoked cell death, and disturbed liver metabolism. An inflammatory repair process with cell proliferation, tissue remodeling, and angiogenesis was rapidly initiated during the first week after chemoembolization. This pilot study provides a comprehensive method to compare different types of DoxMS in healthy animals or tumor models.
KeywordsDrug-loaded microspheres Doxorubicin Liver chemoembolization DNA-microarrays
Conflict of interest
The authors declared that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.
- 23.Dembele D, Jost B, Thibault-Carpentier C et al (2007) Zoe: a user friendly tool for filtering microarray data. In: Proceedings JOBIM Marseille, FranceGoogle Scholar
- 33.Page C, Curtis M, Sutter M et al (1997) Integrated pharmacology. DeBoeck Université, BrusselsGoogle Scholar
- 34.Schroder JM (1992) The neutrophil-activating peptide-1/interleukin-8, a novel neutrophil chemotactic cytokine. Arch Immunol Ther Exp (Warsz) 40:23–31Google Scholar
- 53.Rang H, Dale M, Ritter J et al (2003) Pharmacology. Churchill Livingstone, LondonGoogle Scholar